Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

811
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

614
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

812
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

1.6K
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
1.6K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

939
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
939

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten Guiding Principles for the Management of Postcardiotomy Cardiogenic Shock: Salvaging the Unsalvageable.

The Annals of thoracic surgery·2026
Same author

Initial Experience of Non-Atriotomy Surgical Ablation During Coronary Artery Bypass Grafting With Preexisting Atrial Fibrillation: A Multicenter Study.

Annals of thoracic surgery short reports·2026
Same author

Long-Term Clinical and Angiographic Outcomes of Internal Thoracic Artery Harvesting Technique.

The Journal of surgical research·2026
Same author

Surgical versus percutaneous revascularization in multivessel non-ST-elevation acute coronary syndrome: a meta-analysis of 77 989 patients.

Coronary artery disease·2026
Same author

Sex-specific differences in coronary blood flow dynamics during coronary artery bypass surgery.

Journal of cardiothoracic surgery·2026
Same author

Robotic Left Atrial Appendage Occlusion: Insights From Real-World Practice.

The international journal of medical robotics + computer assisted surgery : MRCAS·2026

Related Experiment Video

Updated: Apr 19, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.3K

SynCardia: the total artificial heart.

Gianluca Torregrossa1, Anelechi Anyanwu1, Fabio Zucchetta1

  • 11 Department of Cardiothoracic Surgery, Mount Sinai Health System, New York, USA ; 2 Department of Cardiac Surgery, University of Padua, Padova, Italy.

Annals of Cardiothoracic Surgery
|December 17, 2014
PubMed
Summary

The SynCardia total artificial heart (TAH) is a definitive treatment for biventricular failure. Surgical techniques have evolved to minimize invasiveness, enabling TAH implantation in complex cases.

Keywords:
SynCardiaTotal artificial heart (TAH)cardiowestimplantation technque

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Apr 19, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.3K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Biomedical Engineering

Background:

  • Biventricular failure necessitates advanced treatment options.
  • The SynCardia total artificial heart (TAH) is a critical intervention for patients ineligible for left ventricular assist devices.
  • TAH implantation is adaptable for diverse complex cardiac conditions.

Purpose of the Study:

  • To detail the evolving implantation techniques for the SynCardia TAH.
  • To highlight methods for minimizing surgical invasiveness and anticipating future procedures.
  • To present TAH implantation experience in challenging patient populations.

Main Methods:

  • Meticulous hemostasis using double-layer sutures.
  • Application of Gore-Tex sheets around the TAH and pericardial cavity.
  • Utilization of tissue expanders to prevent pericardial cavity contraction.

Main Results:

  • TAH implantation techniques are adaptable to various advanced heart failure scenarios.
  • Surgical advancements focus on minimizing invasiveness and managing complex anatomies.
  • Successful TAH implantation demonstrated in challenging cases including small chest cavities, congenital heart defects, and ECMO use.

Conclusions:

  • The SynCardia TAH offers a definitive solution for biventricular failure.
  • Evolving surgical techniques enhance TAH applicability and patient outcomes.
  • TAH implantation is feasible and effective even in highly complex cardiac conditions.